Merck & Co., Inc. Stock price

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 04:00:01 2024-02-09 pm EST 5-day change 1st Jan Change
125.4 USD -0.92% Intraday chart for Merck & Co., Inc. -0.76% +15.07%
Sales 2023 60.12B Sales 2024 * 63.48B Capitalization 318B
Net income 2023 365M Net income 2024 * 19.55B EV / Sales 2023 4.6 x
Net Debt 2023 * 28.54B Net Debt 2024 * 18.76B EV / Sales 2024 * 5.3 x
P/E ratio 2023
779 x
P/E ratio 2024 *
16.1 x
Employees 68,000
Yield 2023 *
2.32%
Yield 2024 *
2.59%
Free-Float 70.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.92%
1 week-0.76%
Current month+3.87%
1 month+5.54%
3 months+23.73%
6 months+18.83%
Current year+15.07%
More quotes
1 week
125.04
Extreme 125.04
128.06
1 month
116.62
Extreme 116.62
128.06
Current year
109.16
Extreme 109.16
128.06
1 year
99.14
Extreme 99.14
128.06
3 years
70.89
Extreme 70.89
128.06
5 years
65.25
Extreme 65.25
128.06
10 years
45.69
Extreme 45.69
128.06
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Compliance Officer 42 18-01-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 66 15-08-31
Director/Board Member 69 18-02-28
More insiders
Date Price Change Volume
24-02-09 125.4 -0.92% 7,891,392
24-02-08 126.6 -0.67% 6,308,268
24-02-07 127.5 +0.47% 6,742,760
24-02-06 126.9 +0.55% 6,152,994
24-02-05 126.2 -0.18% 8,027,717

Delayed Quote Nyse, February 09, 2024 at 04:00 pm EST

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
125.4 USD
Average target price
131.8 USD
Spread / Average Target
+5.07%
Consensus
1st Jan change Capi.
+15.07% 318 B $
+26.97% 666 B $
+19.17% 536 B $
+0.01% 377 B $
+12.33% 307 B $
-8.02% 207 B $
+4.05% 206 B $
-7.92% 191 B $
-4.27% 156 B $
-3.63% 117 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Merck & Co., Inc. - Nyse
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer